Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma.
mucinous
ovarian cancer
prognosis
relapse
survival
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 Nov 2021
21 Nov 2021
Historique:
received:
28
09
2021
revised:
17
11
2021
accepted:
18
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
Mucinous ovarian carcinoma (MOC) is a unique form of ovarian cancer. MOC typically presents at early stage but demonstrates intrinsic chemoresistance; treatment of advanced-stage and relapsed disease is therefore challenging. We harness a large retrospective MOC cohort to identify factors associated with recurrence risk and survival. A total of 151 MOC patients were included. The 5 year disease-specific survival (DSS) was 84.5%. Risk of subsequent recurrence after a disease-free period of 2 and 5 years was low (8.3% and 5.6% over the next 10 years). The majority of cases were FIGO stage I (35.6% IA, 43.0% IC). Multivariable analysis identified stage and pathological grade as independently associated with DSS (
Identifiants
pubmed: 34830992
pii: cancers13225839
doi: 10.3390/cancers13225839
pmc: PMC8616033
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Cancer Research UK
Pays : United Kingdom
Organisme : Target Ovarian Cancer
Organisme : The Nicola Murray Foundation
Références
Am J Surg Pathol. 2003 Jul;27(7):985-93
pubmed: 12826891
Int J Gynecol Cancer. 2018 Jun;28(5):915-924
pubmed: 29561302
Anticancer Res. 2005 Sep-Oct;25(5):3501-5
pubmed: 16101169
Anticancer Res. 2010 Feb;30(2):653-60
pubmed: 20332485
Gynecol Oncol. 2002 Mar;84(3):399-403
pubmed: 11855877
Gynecol Oncol. 2019 Aug;154(2):302-307
pubmed: 31155308
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S14-9
pubmed: 25341574
Gynecol Oncol. 2019 Jun;153(3):541-548
pubmed: 31005287
Front Oncol. 2019 Aug 06;9:639
pubmed: 31448220
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Gynecol Oncol. 2019 Sep;154(3):505-515
pubmed: 31279493
Front Oncol. 2018 Dec 04;8:577
pubmed: 30564556
Gynecol Oncol. 2005 May;97(2):436-41
pubmed: 15863142
J Clin Oncol. 2014 May 1;32(13):1302-8
pubmed: 24637997
Ann Oncol. 2016 Apr;27 Suppl 1:i53-i57
pubmed: 27141073
Lancet Oncol. 2016 Nov;17(11):1579-1589
pubmed: 27617661
Lancet Oncol. 2016 Feb;17(2):e70-e80
pubmed: 26868356
J Clin Oncol. 2004 Mar 15;22(6):1040-4
pubmed: 15020606
J Natl Cancer Inst. 2019 Jan 1;111(1):60-68
pubmed: 29718305
J Clin Pathol. 2012 Jul;65(7):596-600
pubmed: 21768188
BJOG. 2020 Oct;127(11):1409-1420
pubmed: 32285600
Gynecol Oncol. 2009 Jul;114(1):48-52
pubmed: 19361839
N Engl J Med. 2019 Mar 28;380(13):1256-1266
pubmed: 30917260
Nat Commun. 2019 Sep 2;10(1):3935
pubmed: 31477716
Cancer. 2010 Mar 15;116(6):1462-8
pubmed: 20108307
Cancer. 2011 Feb 1;117(3):554-62
pubmed: 20862744